RecruitingNCT07480720

Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease

Relationship Between Systemic Inflammation, Thyroid Autoimmunity, and Neuroretinal Structures in Graves Disease


Sponsor

Elazıg Fethi Sekin Sehir Hastanesi

Enrollment

100 participants

Start Date

Mar 1, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

This retrospective observational study aims to evaluate the relationship between systemic inflammatory parameters, thyroid autoimmunity markers, and neuroretinal structures in patients with Graves disease. Medical records of patients diagnosed with Graves disease and healthy control subjects evaluated at Elazığ Fethi Sekin City Hospital between August 2018 and January 2026 will be reviewed. Optical coherence tomography (OCT) measurements, including macular thickness and peripapillary retinal nerve fiber layer (RNFL) thickness, will be analyzed. Laboratory parameters such as complete blood count-derived inflammatory indices, C-reactive protein, thyroid function tests, and thyroid autoantibodies will also be recorded. The study will compare neuroretinal parameters between healthy controls, Graves disease patients without ophthalmopathy, and Graves disease patients with ophthalmopathy, and will investigate potential associations between systemic inflammation, thyroid autoimmunity, and neuroretinal structural changes.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Age ≥ 18 years
  • Diagnosis of Graves' disease (for the patient group)
  • No known thyroid disease in healthy control participants
  • Availability of optical coherence tomography (OCT) measurements and laboratory data
  • Time interval between OCT examination and blood sampling ≤ 10 days

Exclusion Criteria6

  • Presence of glaucoma, optic neuropathy, or retinal vascular diseases
  • Macular diseases, uveitis, or severe refractive error (high myopia \>6 diopters)
  • Diabetic retinopathy
  • History of previous intraocular surgery
  • History of active infection, malignancy, or systemic inflammatory disease
  • Poor-quality OCT measurements (segmentation errors or low signal strength)

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Fethi Sekin City Hospital

Elâzığ, Elaziğ, Turkey (Türkiye)

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07480720


Related Trials